Skip to main content

Table 2 Dose escalation scheme, treatment delivery and cycle-one dose-limiting toxicity (DLTs)

From: A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients

Cohort Number

Dose level (mg/m2/wk)

Dose increment

Number of patients

Total number of cycles (median per patient)

Total number of infusions (median per patient)

Number of patients with cycle-one DLT

1

135

-

3

9 (2)

32 (6)

0

2

270

100%

6

17 (2)

50 (6)

0

3

540

100%

6

11 (2)

30 (5)

1a

4

675

25%

7

12 (2)

33 (5)

0

5

900

33%

4

6 (1.5)

15 (4)

2b

  1. agrade 4 thrombocytopenia; bgrade 4 thrombocytopenia and grade 4 neutropenia lasting > 5 day